Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T (CAR T) cell technology. The company's CAR T product candidates include MB-101, a IL13Ra2 CAR T cell program which is in Phase I clinical study for glioblastoma; and MB-102, a CD123 CAR T cell program to treat acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm; and MB-106, a CD20 CAR T cell program that is in Phase I clinical study for the treatment of B cell non-Hodgkin lymphoma. It also develops MB-104, a CS1 CAR T, which is in Preclinical study for multiple myeloma and light chain amyloidosisy; MB-103, a human epidermal growth factor receptor 2 CAR T that is in Preclinical study to treat glioblastoma multiforme and metastatic breast cancer to brain; and MB-105, a prostate stem-cell antigen CAR T for prostate and pancreatic cancers. The company has a partnership agreement with the City of Hope National Medical Center and Fred Hutchinson Cancer Research Center to develop proprietary CAR T therapies across various cancers. It also holds a license agreement with Harvard University; and a research collaboration agreement with Beth Israel Deaconess Medical Center for the development of CRISPR/Cas9-enhanced CAR T therapies for the treatment of cancer. The company was incorporated in 2015 and is based in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MBIO
CUSIPN/A
Phone781-652-4500
Debt
Debt-to-Equity RatioN/A
Current Ratio13.11
Quick Ratio13.11
Price-To-Earnings
Trailing P/E Ratio-5.96
Forward P/E Ratio-5.32
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.27 per share
Price / Book1.97
Profitability
EPS (Most Recent Fiscal Year)($0.75)
Net Income$-31,280,000.00
Net MarginsN/A
Return on Equity-41.10%
Return on Assets-38.46%
Miscellaneous
Employees6
Outstanding Shares27,260,000
Market Cap$136.04 million
Mustang Bio (NASDAQ:MBIO) Frequently Asked Questions
What is Mustang Bio's stock symbol?
Mustang Bio trades on the NASDAQ under the ticker symbol "MBIO."
How were Mustang Bio's earnings last quarter?
Mustang Bio Inc (NASDAQ:MBIO) released its quarterly earnings data on Monday, August, 13th. The company reported ($0.19) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.25) by $0.06. View Mustang Bio's Earnings History.
When is Mustang Bio's next earnings date?
What price target have analysts set for MBIO?
2 analysts have issued twelve-month price objectives for Mustang Bio's stock. Their forecasts range from $18.00 to $18.00. On average, they anticipate Mustang Bio's stock price to reach $18.00 in the next year. This suggests a possible upside of 302.7% from the stock's current price. View Analyst Price Targets for Mustang Bio.
What is the consensus analysts' recommendation for Mustang Bio?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mustang Bio in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mustang Bio.
Are investors shorting Mustang Bio?
Mustang Bio saw a decrease in short interest during the month of September. As of September 28th, there was short interest totalling 514,116 shares, a decrease of 33.4% from the September 14th total of 771,836 shares. Based on an average daily trading volume, of 53,561 shares, the short-interest ratio is currently 9.6 days. Currently, 3.3% of the company's shares are short sold. View Mustang Bio's Current Options Chain.
Who are some of Mustang Bio's key competitors?
Some companies that are related to Mustang Bio include Principia Biopharma (PRNB), Ra Pharmaceuticals (RARX), Arcus Biosciences (RCUS), Prothena (PRTA), Five Prime Therapeutics (FPRX), Arvinas (ARVN), Aduro BioTech (ADRO), Rigel Pharmaceuticals (RIGL), Akebia Therapeutics (AKBA), Kezar Life Sciences (KZR), Adamas Pharmaceuticals (ADMS), Stemline Therapeutics (STML), Progenics Pharmaceuticals (PGNX), Aurinia Pharmaceuticals (AUPH) and ArQule (ARQL).
Who are Mustang Bio's key executives?
Mustang Bio's management team includes the folowing people:
- Mr. Michael S. Weiss, Exec. Chairman (Age 52)
- Dr. Manuel Litchman, Pres, CEO & Director (Age 64)
- Mr. David Jay Horin CPA, Interim Chief Financial Officer (Age 50)
- Mr. Brian K. Achenbach, VP of Fin. & Corp. Controller (Age 53)
- Dr. Knut Niss, Chief Technology Officer
How do I buy shares of Mustang Bio?
Shares of MBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mustang Bio's stock price today?
One share of MBIO stock can currently be purchased for approximately $4.47.
How big of a company is Mustang Bio?
Mustang Bio has a market capitalization of $136.04 million. The company earns $-31,280,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. Mustang Bio employs 6 workers across the globe.
What is Mustang Bio's official website?
How can I contact Mustang Bio?
Mustang Bio's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]
MarketBeat Community Rating for Mustang Bio (NASDAQ MBIO)
MarketBeat's community ratings are surveys of what our community members think about Mustang Bio and other stocks. Vote "Outperform" if you believe MBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
